147 related articles for article (PubMed ID: 21154793)
1. Towards elucidation of the role of ubiquitination in the pathogenesis of Parkinson's disease with semisynthetic ubiquitinated α-synuclein.
Hejjaoui M; Haj-Yahya M; Kumar KS; Brik A; Lashuel HA
Angew Chem Int Ed Engl; 2011 Jan; 50(2):405-9. PubMed ID: 21154793
[No Abstract] [Full Text] [Related]
2. Lifetime proteomic profiling of an A30P alpha-synuclein Drosophila model of Parkinson's disease.
Xun Z; Sowell RA; Kaufman TC; Clemmer DE
J Proteome Res; 2007 Sep; 6(9):3729-38. PubMed ID: 17683129
[TBL] [Abstract][Full Text] [Related]
3. Proteomics of Caenorhabditis elegans over-expressing human alpha-synuclein analyzed by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry: identification of actin and several ribosomal proteins as negative markers at early Parkinson's disease stages.
Ichibangase T; Saimaru H; Takamura N; Kuwahara T; Koyama A; Iwatsubo T; Imai K
Biomed Chromatogr; 2008 Mar; 22(3):232-4. PubMed ID: 17939164
[TBL] [Abstract][Full Text] [Related]
4. Controlling the mass action of alpha-synuclein in Parkinson's disease.
Kim C; Lee SJ
J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
[TBL] [Abstract][Full Text] [Related]
5. Threonine 53 in alpha-synuclein is conserved in long-living non-primate animals.
Larsen K; Hedegaard C; Bertelsen MF; Bendixen C
Biochem Biophys Res Commun; 2009 Sep; 387(3):602-5. PubMed ID: 19619507
[TBL] [Abstract][Full Text] [Related]
6. Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides.
Di Pasquale E; Fantini J; Chahinian H; Maresca M; Taïeb N; Yahi N
J Mol Biol; 2010 Mar; 397(1):202-18. PubMed ID: 20114052
[TBL] [Abstract][Full Text] [Related]
7. Binding of Cu(II) to human alpha-synucleins: comparison of wild type and the point mutations associated with the familial Parkinson's disease.
Hong L; Simon JD
J Phys Chem B; 2009 Jul; 113(28):9551-61. PubMed ID: 19548659
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein selectively binds to anionic phospholipids embedded in liquid-disordered domains.
Stöckl M; Fischer P; Wanker E; Herrmann A
J Mol Biol; 2008 Feb; 375(5):1394-404. PubMed ID: 18082181
[TBL] [Abstract][Full Text] [Related]
9. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric fluorescence detection of early stages in the amyloid protein aggregation of pyrene-labeled alpha-synuclein.
Thirunavukkuarasu S; Jares-Erijman EA; Jovin TM
J Mol Biol; 2008 May; 378(5):1064-73. PubMed ID: 18433772
[TBL] [Abstract][Full Text] [Related]
11. DnaK/DnaJ/GrpE of Hsp70 system have differing effects on alpha-synuclein fibrillation involved in Parkinson's disease.
Ahmad A
Int J Biol Macromol; 2010 Mar; 46(2):275-9. PubMed ID: 20060408
[TBL] [Abstract][Full Text] [Related]
12. Thermodynamics imprinting reveals differential binding of metals to alpha-synuclein: relevance to Parkinson's disease.
Bharathi ; Rao KS
Biochem Biophys Res Commun; 2007 Jul; 359(1):115-20. PubMed ID: 17531952
[TBL] [Abstract][Full Text] [Related]
13. Characterization of inhibitor-bound alpha-synuclein dimer: role of alpha-synuclein N-terminal region in dimerization and inhibitor binding.
Yamaguchi Y; Masuda M; Sasakawa H; Nonaka T; Hanashima S; Hisanaga S; Kato K; Hasegawa M
J Mol Biol; 2010 Jan; 395(3):445-56. PubMed ID: 19895818
[TBL] [Abstract][Full Text] [Related]
14. Exploring the Roles of Post-Translational Modifications in the Pathogenesis of Parkinson's Disease Using Synthetic and Semisynthetic Modified α-Synuclein.
Chen H; Zhao YF; Chen YX; Li YM
ACS Chem Neurosci; 2019 Feb; 10(2):910-921. PubMed ID: 30628768
[TBL] [Abstract][Full Text] [Related]
15. Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis.
Alberio T; Bossi AM; Milli A; Parma E; Gariboldi MB; Tosi G; Lopiano L; Fasano M
FEBS J; 2010 Dec; 277(23):4909-19. PubMed ID: 20977677
[TBL] [Abstract][Full Text] [Related]
16. G protein-coupled receptor kinase 5, overexpressed in the alpha-synuclein up-regulation model of Parkinson's disease, regulates bcl-2 expression.
Liu P; Wang X; Gao N; Zhu H; Dai X; Xu Y; Ma C; Huang L; Liu Y; Qin C
Brain Res; 2010 Jan; 1307():134-41. PubMed ID: 19852948
[TBL] [Abstract][Full Text] [Related]
17. Semisynthetic, site-specific ubiquitin modification of α-synuclein reveals differential effects on aggregation.
Meier F; Abeywardana T; Dhall A; Marotta NP; Varkey J; Langen R; Chatterjee C; Pratt MR
J Am Chem Soc; 2012 Mar; 134(12):5468-71. PubMed ID: 22404520
[TBL] [Abstract][Full Text] [Related]
18. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.
Oueslati A; Fournier M; Lashuel HA
Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitination of alpha-synuclein.
Nonaka T; Iwatsubo T; Hasegawa M
Biochemistry; 2005 Jan; 44(1):361-8. PubMed ID: 15628878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]